Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: (R)-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737)
Authors:
Open Access
- 23 May 2016
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 59 (11) , 5221-5237
Abstract
Multiparameter optimization of a series of 5-((4-aminopyridin-2-yl)amino)pyrazine-2-carbonitriles resulted in the identification of a potent and selective oral CHK1 preclinical development candidate with in vivo efficacy as a potentiator of deoxyribonucleic acid (DNA) damaging chemotherapy and as a single agent. Cellular mechanism of action assays were used to give an integrated assessment of compound selectivity during optimization resulting in a highly CHK1 selective adenosine triphosphate (ATP) competitive inhibitor. A single substituent vector directed away from the CHK1 kinase active site was unexpectedly found to drive the selective cellular efficacy of the compounds. Both CHK1 potency and off-target human ether-a-go-go-related gene (hERG) ion channel inhibition were dependent on lipophilicity and basicity in this series. Optimization of CHK1 cellular potency and in vivo pharmacokinetic–pharmacodynamic (PK–PD) properties gave a compound with low predicted doses and exposures in humans which mitigated the residual weak in vitro hERG inhibition.Keywords
Funding Information
- Engineering and Physical Sciences Research Council (C1060/A10334)
- Medical Research Council (C1060/A10334)
- Institute of Cancer Research
- Cancer Research UK (C1060/A10334, C309/A11566, C309/A8274)
- Department of Health, United Kingdom (C1060/A10334)
- Sareum Limited
This publication has 46 references indexed in Scilit:
- Discovery of 3-Alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as Selective, Orally Bioavailable CHK1 InhibitorsJournal of Medicinal Chemistry, 2012
- Structure-Guided Evolution of Potent and Selective CHK1 Inhibitors through Scaffold MorphingJournal of Medicinal Chemistry, 2011
- RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastomaProceedings of the National Academy of Sciences, 2011
- Guidelines for the welfare and use of animals in cancer researchBritish Journal of Cancer, 2010
- PHENIX: a comprehensive Python-based system for macromolecular structure solutionActa Crystallographica Section D Structural Biology, 2010
- XDSActa Crystallographica Section D Structural Biology, 2010
- Measuring and interpreting the selectivity of protein kinase inhibitorsJournal of Chemical Biology, 2009
- Sunitinib‐Induced Cardiotoxicity Is Mediated by Off‐Target Inhibition of AMP‐Activated Protein KinaseClinical and Translational Science, 2009
- Scaling and assessment of data qualityActa Crystallographica Section D Structural Biology, 2005
- Coot: model-building tools for molecular graphicsActa Crystallographica Section D Structural Biology, 2004